Phage Therapy against Staphylococcus aureus: Selection and Optimization of Production Protocols of Novel Broad-Spectrum Silviavirus Phages

Background: Phage therapy a promising antimicrobial strategy to address antimicrobial resistance for infections caused by the major human pathogen Staphylococcus aureus. Development of therapeutic phages for human use should follow pharmaceutical standards, including selection of strictly lytic bact...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 14; no. 9; p. 1885
Main Authors Kolenda, Camille, Medina, Mathieu, Bonhomme, Mélanie, Laumay, Floriane, Roussel-Gaillard, Tiphaine, Martins-Simoes, Patricia, Tristan, Anne, Pirot, Fabrice, Ferry, Tristan, Laurent, Frédéric
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 06.09.2022
MDPI
Subjects
Antibiotics
Antimicrobial agents
bacteriophages
Gene expression
Genomes
Optimization
Pathogens
phage therapy
phages
production
Proteins
Staphylococcus
Virulence
yield
France
United States > US
Germany
Online AccessGet full text

Cover

More Information
Summary:Background: Phage therapy a promising antimicrobial strategy to address antimicrobial resistance for infections caused by the major human pathogen Staphylococcus aureus. Development of therapeutic phages for human use should follow pharmaceutical standards, including selection of strictly lytic bacteriophages with high therapeutic potential and optimization of their production process. Results: Here, we describe three novel Silviavirus phages active against 82% of a large collection of strains (n = 150) representative of various methicillin-susceptible and -resistant S. aureus clones circulating worldwide. We also investigated the optimization of the efficiency and safety of phage amplification protocols. To do so, we selected a well-characterized bacterial strain in order to (i) maximize phage production yields, reaching phage titres of 1011 PFU/mL in only 4 h; and (ii) facilitate phage purity while minimizing the risk of the presence of contaminants originating from the bacterial host; i.e., secreted virulence factors or induced temperate phages. Conclusions: In sum, we propose a quality-by-design approach for the amplification of broad-spectrum anti-S. aureus phages, facilitating the subsequent steps of the manufacturing process; namely, purification and quality control.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors equally contributed to this work.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics14091885